Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Our old friend Allogene ALLO with a market cap of 4 billion:

Abstract Based on Data Cutoff in January 2020 Represents Limited Data Set of Nine Evaluable Patients Treated at Lower Dose (39mg) ALLO-647; Three Patients Achieved a Complete Response (CR).

Two patients (22.2%) developed cytokine release syndrome (one Gr1 and one Gr2) that resolved within 72 hours without steroids or tocilizumab.

In this limited dataset with a small number of patients, the overall response rate (ORR) was 78% (95% exact CI: 40%, 97%) with three complete responses (CR) and four partial responses (PR).